R
Russell W. Walker
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 47
Citations - 2657
Russell W. Walker is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Lisuride & Levodopa. The author has an hindex of 27, co-authored 47 publications receiving 2568 citations. Previous affiliations of Russell W. Walker include New York University & St. Joseph's Hospital and Medical Center.
Papers
More filters
Journal ArticleDOI
Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia.
Eric Lancaster,Maartje G. Huijbers,Vered Bar,Anna Boronat,Andrew K. Wong,Eugenia Martinez-Hernandez,Christina A. Wilson,Dina A. Jacobs,Meizan Lai,Russell W. Walker,Francesc Graus,Luis Bataller,Isabel Illa,Sander Markx,Kevin A. Strauss,Kevin A. Strauss,Kevin A. Strauss,Elior Peles,Steven S. Scherer,Josep Dalmau +19 more
TL;DR: Clinical and immunological investigations of contactin‐associated protein‐like 2 (Caspr2), an autoantigen of encephalitis and peripheral nerve hyperexcitability (PNH) previously attributed to voltage‐gated potassium channels (VGKC), are reported.
Journal ArticleDOI
Chemotherapy without irradiation--a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study.
Casilda Balmaceda,Glenn Heller,Marc K. Rosenblum,Blanca Diez,Judith G. Villablanca,Stewart J. Kellie,P Maher,V Vlamis,Russell W. Walker,Steven A. Leibel,Jonathan L. Finlay +10 more
TL;DR: Chemotherapy-only regimens for CNS GCT, although encouraging, should continue to be used only in the setting of formal clinical trials.
Journal ArticleDOI
Carboplatin and recurrent childhood brain tumors.
Jeffrey C. Allen,Russell W. Walker,Enrique Luks,Mark T. Jennings,Sarah Barfoot,Charlotte Tan +5 more
TL;DR: Because of its low potential for auditory, renal, and emetic toxicity, ease of administration, and high disease-specific activity, carboplatin deserves further study in multiagent phase II and III trials, especially in chemotherapy-sensitive diseases such as medulloblastoma.
Journal ArticleDOI
Cisplatin in the treatment of recurrent childhood primary brain tumors.
Russell W. Walker,J C Allen +1 more
TL;DR: Toxicity was tolerable, although it precluded further therapy in five patients, and response rate was 13 of 32 (41%).
Journal ArticleDOI
MR of Cranial and Spinal Meningeal Carcinomatosis: Comparison with CT and Myelography
TL;DR: In this paper, cranial CT and MR images were evaluated by 29 patients with histologically proved primary neoplasms, focal neurologic deficits, and positive CSF cytology.